02/07/2024
Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to [email protected].
01/31/2024
Mycovia Pharmaceuticals, Inc. Announces Publication of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating the Efficacy and Safety of VIVJOA® (Oteseconazole) Versus Fluconazole in Women with Vulvovaginal Candidiasis (VVC) in the Journal Antimicrobial Agents and Chemotherapy
08/21/2023
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
08/25/2022
Mycovia Pharmaceuticals’ Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA™ (oteseconazole) in Women with Recurrent Vulvovaginal Candidiasis (RVVC) Published in the American Journal of Obstetrics and Gynecology
08/02/2022
